Iadademstat + Paclitaxel
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Small-cell Lung Cancer
Conditions
Small-cell Lung Cancer, Neuroendocrine Carcinoma
Trial Timeline
Dec 21, 2022 → Jul 23, 2025
NCT ID
NCT05420636About Iadademstat + Paclitaxel
Iadademstat + Paclitaxel is a phase 2 stage product being developed by Oryzon Genomics for Small-cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05420636. Target conditions include Small-cell Lung Cancer, Neuroendocrine Carcinoma.
What happened to similar drugs?
7 of 20 similar drugs in Small-cell Lung Cancer were approved
Approved (7) Terminated (7) Active (8)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05420636 | Phase 2 | Terminated |
Competing Products
20 competing products in Small-cell Lung Cancer